Cocrystal Pharma Salute del bilancio

Salute finanziaria criteri di controllo 4/6

Cocrystal Pharma ha un patrimonio netto totale di $12.7M e un debito totale di $0.0, che porta il suo rapporto debito/patrimonio netto a 0%. Le sue attività totali e le sue passività totali sono rispettivamente $16.2M e $3.5M.

Informazioni chiave

Rapporto debito/patrimonio netto

US$0

Debito

Indice di copertura degli interessi	n/a
Contanti	US$13.02m
Patrimonio netto	US$12.70m
Totale passività	US$3.53m
Totale attività	US$16.23m

Aggiornamenti recenti sulla salute finanziaria

Companies Like Cocrystal Pharma (NASDAQ:COCP) Are In A Position To Invest In Growth

Nov 19

Recent updates

Here's Why We're Watching Cocrystal Pharma's (NASDAQ:COCP) Cash Burn Situation

Oct 18

Cocrystal selects its antiviral drug candidate to develop as a treatment for COVID-19

Oct 11

Cocrystal Pharma GAAP EPS of -$0.25 misses by $0.21

Aug 15

Cocrystal Pharma (NASDAQ:COCP) Is In A Good Position To Deliver On Growth Plans

Aug 14

Cocrystal engages Open Orphan to conduct mid-stage trial of oral influenza drug in UK

Aug 08

We're Not Very Worried About Cocrystal Pharma's (NASDAQ:COCP) Cash Burn Rate

Mar 19

Companies Like Cocrystal Pharma (NASDAQ:COCP) Are In A Position To Invest In Growth

Nov 19

We Think Cocrystal Pharma (NASDAQ:COCP) Can Afford To Drive Business Growth

Aug 06

Cocrystal’s soars 11% as CDI-45205 shows excellent antiviral activity against SARS-CoV-2 and variants

Jun 14

We Think Cocrystal Pharma (NASDAQ:COCP) Needs To Drive Business Growth Carefully

May 05

Cocrystal Pharma updates on COVID-19 antiviral development programs

May 03

Investors Who Bought Cocrystal Pharma (NASDAQ:COCP) Shares A Year Ago Are Now Up 94%

Mar 13

What Is The Ownership Structure Like For Cocrystal Pharma, Inc. (NASDAQ:COCP)?

Jan 24

Cocrystal sees 2021 cash burn of $800k a month

Jan 11

Cocrystal Pharma to test CDI-45205 against coronaviruses

Dec 22

Is Cocrystal Pharma (NASDAQ:COCP) In A Good Position To Invest In Growth?

Dec 20

Analisi della posizione finanziaria

Passività a breve termine: Le attività a breve termine ( $14.3M ) di COCP superano le sue passività a breve termine ( $1.9M ).

Passività a lungo termine: Le attività a breve termine di COCP ( $14.3M ) superano le sue passività a lungo termine ( $1.6M ).

Storia e analisi del rapporto debito/patrimonio netto

Livello di debito: COCP è esente da debiti.

Riduzione del debito: COCP non aveva debiti 5 anni fa.

Bilancio

Analisi della pista di contanti

Per le società che in passato sono state mediamente in perdita, valutiamo se hanno almeno un anno di liquidità.

Pista di liquidità stabile: COCP ha meno di un anno di cash runway in base al suo attuale free cash flow.

Previsione Cash Runway: COCP ha meno di un anno di liquidità disponibile se il flusso di cassa libero continua a ridursi ai tassi storici del 22.8 % ogni anno

Scoprire le aziende sane

Analisi aziendale e situazione dei dati finanziari

Dati	Ultimo aggiornamento (ora UTC)
Analisi dell'azienda	2024/12/29 12:10
Prezzo dell'azione a fine giornata	2024/12/27 00:00
Guadagni	2024/09/30
Guadagni annuali	2023/12/31

Fonti dei dati

I dati utilizzati nella nostra analisi aziendale provengono da S&P Global Market Intelligence LLC. I seguenti dati sono utilizzati nel nostro modello di analisi per generare questo report. I dati sono normalizzati, il che può comportare un ritardo nella disponibilità della fonte.

Pacchetto	Dati	Tempistica	Esempio Fonte USA ^*
Dati finanziari della società	10 anni	Conto economico Rendiconto finanziario Bilancio	Modulo SEC 10-K Modulo SEC 10-Q
Stime di consenso degli analisti	+3 anni	Previsioni finanziarie Obiettivi di prezzo degli analisti	Rapporti di ricerca degli analisti Blue Matrix
Prezzi di mercato	30 anni	Prezzi delle azioni Dividendi, scissioni e azioni	Dati di mercato ICE Modulo SEC S-1
Proprietà	10 anni	Top azionisti Insider trading	Modulo 4 SEC Modulo 13D SEC
Gestione	10 anni	Team di leadership Consiglio di amministrazione	Modulo SEC 10-K Modulo SEC DEF 14A
Sviluppi principali	10 anni	Annunci aziendali	Modulo 8-K SEC

^* esempio per i titoli statunitensi, per quelli non statunitensi si utilizzano forme e fonti normative equivalenti.

Se non specificato, tutti i dati finanziari si basano su un periodo annuale ma vengono aggiornati trimestralmente. Si tratta dei cosiddetti dati TTM (Trailing Twelve Month) o LTM (Last Twelve Month). Per saperne di più , cliccate qui.

Modello di analisi e Snowflake

I dettagli del modello di analisi utilizzato per generare questo report sono disponibili sulla nostra pagina Github; abbiamo anche guide su come utilizzare i nostri report e tutorial su Youtube.

Scoprite il team di livello mondiale che ha progettato e realizzato il modello di analisi Simply Wall St.

Metriche di settore e industriali

Le nostre metriche di settore e di sezione sono calcolate ogni 6 ore da Simply Wall St; i dettagli del nostro processo sono disponibili su .

Fonti analitiche

Cocrystal Pharma, Inc. è coperta da 5 analisti. 3 di questi analisti ha fornito le stime di fatturato o di utile utilizzate come input per il nostro report. Le stime degli analisti vengono aggiornate nel corso della giornata.

Analista	Istituzione
Raghuram Selvaraju	H.C. Wainwright & Co.
Ahu Demir	NOBLE Capital Markets, Inc.
Robert LeBoyer	NOBLE Capital Markets, Inc.

Cocrystal Pharma Salute del bilancio

Salute finanziaria criteri di controllo 4/6

Informazioni chiave

Aggiornamenti recenti sulla salute finanziaria

Here's Why We're Watching Cocrystal Pharma's (NASDAQ:COCP) Cash Burn Situation

Cocrystal Pharma Announces a 1-for-12 Reverse Stock Split

Cocrystal Pharma (NASDAQ:COCP) Is In A Good Position To Deliver On Growth Plans

Nasdaq Grants 180 Days to Cocrystal Pharma to Regain Compliance

We're Not Very Worried About Cocrystal Pharma's (NASDAQ:COCP) Cash Burn Rate

Companies Like Cocrystal Pharma (NASDAQ:COCP) Are In A Position To Invest In Growth

Recent updates

New major risk - Financial position

Here's Why We're Watching Cocrystal Pharma's (NASDAQ:COCP) Cash Burn Situation

Price target decreased by 11% to US$8.00

Cocrystal Pharma, Inc. Reports Favorable Results from Single-Ascending Dose Cohorts of Phase 1 Study with CDI-988, its Oral Pan-Viral Norovirus/Coronavirus Protease Inhibitor

Cocrystal Pharma Advances Cc-42344 in Influenza A Phase 2A Study, Expects Topline Results by Late 2024

Cocrystal Pharma, Inc. Announces Completion of Enrollment of 78 Subjects

Cocrystal Pharma, Inc. Provides an Update on the Clinical Development of its Novel, Broad-Spectrum Antiviral Investment Candidates

Cocrystal Pharma, Inc. Announces First-Patient-In for Phase 2A Human Challenge Study Evaluating Oral Cc-42344 in Pandemic and Seasonal Influenza A

Cocrystal Pharma, Inc. Highlights Its Novel Inhaled and Oral Influenza A Antiviral Cc-42344 At the World Vaccine Congress West Coast

Cocrystal Pharma, Inc. Doses First Subjects in Clinical Study of CDI-988 for Pandemic Norovirus and Coronavirus

Cocrystal Pharma Reports Highly Favorable Safety and Tolerability Results from a Phase 1 Study with its Oral Antiviral CC-42344 for the Treatment of Pandemic and Seasonal Influenza A

Cocrystal Pharma, Inc. Announces Favorable Safety Data from the Phase 1 Study with Oral Antiviral CC-42344 for the Treatment of Pandemic and Seasonal Influenza A

Cocrystal Pharma, Inc. Announces Enrollment Completed in Phase 1 Influenza A Study with Cocrystal Pharma's Oral Antiviral Candidate Cc-42344

Cocrystal selects its antiviral drug candidate to develop as a treatment for COVID-19

Cocrystal Pharma Announces a 1-for-12 Reverse Stock Split

Consensus forecasts updated

Consensus forecasts updated

Cocrystal Pharma GAAP EPS of -$0.25 misses by $0.21

Cocrystal Pharma (NASDAQ:COCP) Is In A Good Position To Deliver On Growth Plans

Cocrystal Pharma Engages CRO to Conduct Phase 2a Human Challenge Influenza A Clinical Trial with Novel, Broad-Spectrum Antiviral Candidate CC-42344

Cocrystal engages Open Orphan to conduct mid-stage trial of oral influenza drug in UK

Cocrystal Pharma, Inc. Reports CC-42344 Pharmacokinetic Data in Influenza A Once-Daily Dosing

Nasdaq Grants 180 Days to Cocrystal Pharma to Regain Compliance

Price target decreased to US$4.08

Cocrystal Pharma, Inc. Reports Favorable Preliminary Data from Phase 1 Initial Cohorts with Cc-42344, a Novel, Broad-Spectrum Influenza A Antiviral

Cocrystal Pharma, Inc., Annual General Meeting, May 18, 2022

We're Not Very Worried About Cocrystal Pharma's (NASDAQ:COCP) Cash Burn Rate

Price target decreased to US$4.08

Cocrystal Pharma Selects Two Lead Antiviral Drug Candidates for its COVID-19 Oral Drug Program

Cocrystal Pharma Receives FDA Guidance to Advance Clinical Development of its COVID-19 Antiviral CDI-45205

Cocrystal Pharma’s Covid-19 Oral and Intranasal/Pulmonary Protease Inhibitors Exhibit Powerful in Vitro Potency Against the Sars-Cov-2 Omicron Variant

Cocrystal Pharma to Discuss Progress with COVID-19 Antiviral Programs and Clinical Strategy During Noble Capital Markets’ Channelchek Virtual Roadshow

Companies Like Cocrystal Pharma (NASDAQ:COCP) Are In A Position To Invest In Growth

Third quarter 2021 earnings released: US$0.04 loss per share (vs US$0.046 loss in 3Q 2020)

We Think Cocrystal Pharma (NASDAQ:COCP) Can Afford To Drive Business Growth

Cocrystal Pharma, Inc. Completes IND-enabling Studies with CC-42344 for the Treatment of Seasonal and Pandemic Influenza A, Plans to initiate a Phase 1 Trial in the Third Quarter

CocrystalPharma, Inc ’s Lead COVID-19 Antiviral CDI-45205 Shown to be Active Against SARS-CoV-2 and Two Prominent SARS-CoV-2 Variants

Cocrystal’s soars 11% as CDI-45205 shows excellent antiviral activity against SARS-CoV-2 and variants

Co-Founder, Chairman & CEO Gary Wilcox has left the company

Board Member recently sold US$1.7m worth of stock

We Think Cocrystal Pharma (NASDAQ:COCP) Needs To Drive Business Growth Carefully

Cocrystal Pharma, Inc. Provides Update on its COVID-19 Antiviral Discovery and Development Programs

Cocrystal Pharma updates on COVID-19 antiviral development programs

Price target decreased to US$4.50

Full year 2020 earnings released: US$0.17 loss per share (vs US$1.51 loss in FY 2019)

Investors Who Bought Cocrystal Pharma (NASDAQ:COCP) Shares A Year Ago Are Now Up 94%

Cocrystal Pharma, Inc. Extends Drug Discovery Collaboration with HitGen and InterX, Inc

Board Member notifies of intention to sell stock

What Is The Ownership Structure Like For Cocrystal Pharma, Inc. (NASDAQ:COCP)?

Board Member notifies of intention to sell stock

Cocrystal Pharma Provides Summary of Upcoming Presentation at the Reimagine Health Research Symposium

Cocrystal Pharma Announces Further Development of Influenza A/B Antiviral Compounds by Merck Under Exclusive Worldwide License and Collaboration Agreement

New 90-day high: US$2.19

Cocrystal sees 2021 cash burn of $800k a month

Cocrystal Pharma to test CDI-45205 against coronaviruses

Is Cocrystal Pharma (NASDAQ:COCP) In A Good Position To Invest In Growth?

New 90-day high: US$1.71

Third quarter 2020 earnings released: US$0.046 loss per share

New 90-day low: US$0.84

Cocrystal Pharma, Inc. Provides Update on Influenza A Program

United States District Court for the District of New Jersey Enters an Order Preliminarily Approving the Stipulation and Agreement of Settlement with Cocrystal Pharma, Inc

New 90-day low - US$0.93

Cocrystal Pharma, Inc. has completed a Follow-on Equity Offering in the amount of $15.000001 million.

New 90-day high - US$2.36

Cocrystal Pharma, Inc.(NasdaqCM:COCP) dropped from Russell Microcap Value Index

Cocrystal Pharma, Inc.(NasdaqCM:COCP) dropped from Russell Microcap Index

Analisi della posizione finanziaria

Storia e analisi del rapporto debito/patrimonio netto

Bilancio